{"name":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","slug":"arqule-inc-a-subsidiary-of-merck-sharp-dohme-llc-a-subsidiary-of-merck-co-inc-ra","ticker":"","exchange":"","domain":"","description":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC (a subsidiary of Merck & Co., Inc.), is a biotechnology company focused on the research and development of targeted cancer therapies. The company has a pipeline of 15 drugs, with several in early-stage clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ARQ 092","genericName":"ARQ 092","slug":"arq-092","indication":"Relapsed or refractory follicular lymphoma","status":"phase_2"},{"name":"ARQ 197 plus erlotinib","genericName":"ARQ 197 plus erlotinib","slug":"arq-197-plus-erlotinib","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"ARQ 501","genericName":"ARQ 501","slug":"arq-501","indication":"Non-small cell lung cancer with ALK rearrangement","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ARQ 501 in combination with gemcitabine","genericName":"ARQ 501 in combination with gemcitabine","slug":"arq-501-in-combination-with-gemcitabine","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"ARQ 092","genericName":"ARQ 092","slug":"arq-092","phase":"phase_2","mechanism":"ARQ 092 is a potent and selective inhibitor of mTORC1/2.","indications":["Relapsed or refractory follicular lymphoma","Relapsed or refractory mantle cell lymphoma"],"catalyst":""},{"name":"ARQ 197 plus erlotinib","genericName":"ARQ 197 plus erlotinib","slug":"arq-197-plus-erlotinib","phase":"phase_2","mechanism":"ARQ 197 is a small molecule inhibitor of c-MET, and when combined with erlotinib, targets the EGFR and c-MET pathways.","indications":["Non-small cell lung cancer","Other cancers with EGFR and c-MET overexpression"],"catalyst":""},{"name":"ARQ 501","genericName":"ARQ 501","slug":"arq-501","phase":"phase_2","mechanism":"ARQ 501 is a selective inhibitor of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase.","indications":["Non-small cell lung cancer with ALK rearrangement"],"catalyst":""},{"name":"ARQ 501 in combination with gemcitabine","genericName":"ARQ 501 in combination with gemcitabine","slug":"arq-501-in-combination-with-gemcitabine","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":4},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}